Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1078 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Biogen Idec Q2 revenue slightly falls

Biogen Idec‘s net income was $304.49m, compared to $294.64m for the same period in the prior year. The company’s income from operations was $410.81m for the second quarter

Impax enrolls patients for IPX066 comparative study

An investigational extended release capsule formulation of carbidopa-levodopa (CD-LD)- IPX066, is aimed to treat motor symptoms of the PD. The randomised, double-blind 2-treatment, 2-period crossover Ascend-PD study enrolled

OraSure plans acquisition of DNA Genotek

Through the $53m acquisition OraSure hopes to strengthen its position in oral fluid diagnostics as DNA Genotek will offer a complementary portfolio of products for easy and reliable

Lupin inks R&D pact with Medicis

As per the terms of the agreement, Medicis is responsible to pay sum of $20m as an upfront payment to Lupin. The tie up allows Lupin to develop

EC grants conditional approval to Biogen MS drug

Fampyra is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). Studies reveal that the sustained release formulation increases conduction of damaged nerves,

Adia Nutrition introduces probiotic chews

Probiotic chews contains 1 billion bacteria per serving and are of good taste due to the presence of natural sweeteners and flavanoids. Probiotic bacteria promote digestive health, immune